ISSN(O): 2320-5407 | ISSN(P): 3107-4928



International Journal of Advanced Research

Publisher's Name: Jana Publication and Research LLP

www.journalijar.com

REVIEWER'S REPORT

Manuscript No.: IJAR-55012

Title: TO COMPARE THE EFFICACY OF ORAL ACETAZOLAMIDE VS EPLERENONE IN PATIENTS OF CENTRAL SEROUS CHORIORETINOPATHY

Recommendation:	Rating	Excel.	Good	Fair	Poor
Accept as it is	Originality			Fair	
Accept after minor revision	Techn. Quality			Fair	
Do not accept (Reasons below)	Clarity			Fair	
	Significance			Fair	

Reviewer Name: Dr. Sumathi

Detailed Reviewer's Report

- 1. Acetazolamide is a prescription only carbonic anhydrase inhibitor medication used to treat several conditions, including glaucoma, altitude sickness, certain types of epilepsy and edema. It works by affecting the body's fluid and acid base balance.
- 2. Eplerenone is a prescription used to treat high blood pressure and heart failure following a heart attack. It belongs to a class of drugs known as potassium sparing diuretics and aldosterone antagonists.
- 3. Chorioretinopathy is an inflammatory condition affecting the retina and the choroid, the blood vessel layer beneath the retina.
- 4. It can causes a buildup of fluid under the retina, leading to vision problems like distorted or blurry central vision.
- 5. Causes include infections, autoimmune disorders, and trauma to the eye, while some forms, like central serous chorioretinopathy, may also be triggered by stress or corticosteroid use.
- 6. Actually research topic is good. But there is no key words.
- 7. Abstract also not given. Very less information are given. Less point of introduction and result part only tables given there is no explanation.

ISSN(O): 2320-5407 | ISSN(P): 3107-4928

International Journal of Advanced Research

Publisher's Name: Jana Publication and Research LLP

www.journalijar.com

REVIEWER'S REPORT

- 8. Discussion and conclusion also very less points.
- 9. Summary points are not given. And totally missed references. With out references how can publish the journal.
- 10. What ever I mentioned it should be rewrite the paper. Other wise it won't eligible to publish.
- 11. Without fail do all those I mentioned before publishing paper.